Effectiveness of KOS-862 in the Treatment of Lung Cancer
This study has been terminated.
Sponsor:
Bristol-Myers Squibb
Information provided by:
Bristol-Myers Squibb
ClinicalTrials.gov Identifier:
NCT00080509
First received: April 5, 2004
Last updated: February 2, 2010
Last verified: November 2009
Tracking Information | |
---|---|
First Received Date ICMJE | April 5, 2004 |
Last Updated Date | February 2, 2010 |
Start Date ICMJE | December 2003 |
Primary Completion Date | |
Current Primary Outcome Measures ICMJE |
NSCLC |
Original Primary Outcome Measures ICMJE | Same as current |
Change History | Complete list of historical versions of study NCT00080509 on ClinicalTrials.gov Archive Site |
Current Secondary Outcome Measures ICMJE | |
Original Secondary Outcome Measures ICMJE | |
Current Other Outcome Measures ICMJE | |
Original Other Outcome Measures ICMJE | |
Descriptive Information | |
Brief Title ICMJE | Effectiveness of KOS-862 in the Treatment of Lung Cancer |
Official Title ICMJE | A Phase 2 Study of KOS-862, Administered Intravenously Weekly for 3 Weeks Every 4 Weeks, in Patients With Non-Small Cell Lung Cancer Who Have Progressed Following Initial Therapy for Advanced or Metastatic Disease |
Brief Summary | The purpose of this study is to determine whether a potential drug known as KOS-862 or "Epothilone D" has an effect as a 2nd line treatment in non-small cell lung cancer (NSCLC) for patients having failed one prior platinum-containing chemotherapy regimen. |
Detailed Description | To determine the antitumor activity, based on the confirmed objective response rate, of KOS-862, administered intravenously weekly for 3 weeks every 4 weeks, in patients with non-small cell lung cancer (NSCLC) whose disease has progressed following initial chemotherapy for advanced or metastatic disease. |
Study Type ICMJE | Interventional |
Study Phase | Phase 2 |
Study Design ICMJE | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
Condition ICMJE | Lung Cancer |
Intervention ICMJE | Drug: KOS-862 |
Study Arm (s) | |
Publications * | |
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|
Recruitment Information | |
Recruitment Status ICMJE | Terminated |
Enrollment ICMJE | 85 |
Completion Date | November 2004 |
Primary Completion Date | |
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
Gender | Both |
Ages | 18 Years and older |
Accepts Healthy Volunteers | No |
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects |
Location Countries ICMJE | |
Administrative Information | |
NCT Number ICMJE | NCT00080509 |
Other Study ID Numbers ICMJE | KOS-201/NO17352 |
Has Data Monitoring Committee | |
Responsible Party | |
Study Sponsor ICMJE | Bristol-Myers Squibb |
Collaborators ICMJE | |
Investigators ICMJE | |
Information Provided By | Bristol-Myers Squibb |
Verification Date | November 2009 |
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |